Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Ann Rheum Dis. 2021 Oct;80(10):e161. doi: 10.1136/annrheumdis-2021-220898. Epub 2021 Jun 29.

Authors

Larissa Valor-Méndez¹, Koray Tascilar², David Simon², Joerg Distler², Arnd Kleyer³, Georg Schett³, Juergen Rech²

Affiliations

¹ Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany [email protected].
² Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
³ Internal Medicine 3, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

PMID: 34187777
DOI: 10.1136/annrheumdis-2021-220898

No abstract available

Keywords: Covid-19; familial mediterranean fever; inflammation; interleukin 1 receptor antagonist protein; vaccination.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines*
Cohort Studies
Humans
Immunogenicity, Vaccine
Immunosuppression Therapy*
RNA, Messenger

Substances

COVID-19 Vaccines
RNA, Messenger